Biogen to Present Data from its Neurology Pipeline at the 2018 International Congress of Parkinson’s Disease and Movement Disorders (MDS)
CAMBRIDGE, Mass., Oct. 03, 2018 (GLOBE NEWSWIRE) --
- Data to be presented from the BIIB092 program for progressive supranuclear palsy and BIIB054 program for Parkinson’s disease highlight Biogen’s commitment to furthering movement disorders research
- Biogen’s Phase 2 PASSPORT study of BIIB092 for PSP has completed enrollment and BIIB092 has received fast track designation by the U.S. Food and Drug Administration for PSP
Biogen Inc. (Nasdaq:BIIB) announced it will present data from its movement disorders portfolio at the upcoming International Congress of Parkinson’s Disease and Movement Disorders (MDS) in Hong Kong (Oct. 5-9, 2018). Data being presented are from Biogen’s research programs evaluating potential treatments for progressive supranuclear palsy (PSP) and Parkinson’s disease (PD) as part of its larger neurology pipeline.
“The data being presented at MDS are a testament to Biogen’s commitment to its goal of delivering innovative therapies for people living with complex, neurodegenerative conditions like PSP and PD,” said Kate Dawson, M.D., vice president of late-stage clinical development at Biogen. “PSP and PD both have significant unmet need, especially for disease modifying therapies, so we look forward to advancing the clinical development programs to help better understand these challenging conditions.”
Biogen PSP presentations will focus on safety data from the Phase 1 long-term extension study and baseline demographics from the Phase 2 PASSPORT study. The company’s BIIB092 program has recently met milestones, including recruitment completion for the Phase 2 PASSPORT study and fast track designation by the U.S. Food and Drug Administration for PSP. PSP is a rare neurodegenerative disease, considered to be a primary tauopathy, characterized by rapidly progressing physical impairments, such as difficulty speaking, swallowing and walking, as well as cognitive/behavioral impairments, such as apathy and dementia.
PD presentations will feature an overview of the design of the BIIB054 SPARK Phase 2 study, which is the most advanced program in Biogen’s PD pipeline. PD is the second most common neurodegenerative disease after Alzheimer’s disease. Motor symptoms of PD include bradykinesia, muscular rigidity, rest tremor and postural and gait impairment.1
Biogen’s presentations highlight:
- Safety analysis of an open-label extension study of BIIB092 in participants with PSP – POSTER, Abstract #43 – Saturday, Oct. 6, 13:45 – 15:15 HKT
- PASSPORT, an ongoing Phase 2 study in patients with PSP– baseline characteristics – POSTER, Abstract #8 – Saturday, Oct. 6, 13:45 – 15:15 HKT
- Prevalence and characteristics of patients with progressive supranuclear palsy (PSP) in US health insurance claims data –POSTER, Abstract #795 – Sunday, Oct. 7, 13:45 – 15:15 HKT
- Burden of progressive supranuclear palsy: a systematic literature review – POSTER, Abstract #921 – Sunday, Oct. 7,13:45 – 15:15 HKT
- Effect of PD medication on disease progression as measured by rate of change in MDS_UPDRS and DaT SBR in PPMI study – POSTER, Abstract #11– Saturday, Oct. 6, 13:45 – 15:15 HKT
- Design and status of the BIIB054 SPARK trial – POSTER, Abstract #39 – Saturday, Oct. 6, 13:45 – 15:15 HKT
- Quantitative assessment of appendicular bradykinesia in PD using wearable sensors – POSTER, Abstract #1131 – Sunday, Oct. 7, 13:45 – 15:15 HKT
- Effects of LDOPA on quantitative gait parameters measured with wearable sensors – POSTER, Abstract #1137 – Sunday, Oct. 7, 13:45 – 15:15 HKT
At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp, and today has the leading portfolio of medicines to treat multiple sclerosis; has introduced the first and only approved treatment for spinal muscular atrophy; and is focused on advancing neuroscience research programs in Alzheimer’s disease and dementia, multiple sclerosis and neuroimmunology, movement disorders, neuromuscular disorders, pain, ophthalmology, neuropsychiatry and acute neurology. Biogen also manufactures and commercializes biosimilars of advanced biologics.
We routinely post information that may be important to investors on our website at www.biogen.com. To learn more, please visit www.biogen.com and follow us on social media – Twitter, LinkedIn, Facebook, YouTube.
Biogen Safe Harbor
This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, about the Phase 1 long-term extension study and Phase 2 study of BIIB092 and the Phase 2 study of BIIB054; the potential clinical effects of BIIB092 and BIIB054; the potential benefits, safety and efficacy of BIIB092 and BIIB054; the identification and treatment of PSP; the potential of Biogen’s commercial business and pipeline programs, including BIIB092 and BIIB054; and risks and uncertainties associated with drug development and commercialization. These statements may be identified by words such as “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “plan,” “possible,” “potential,” “will” and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements or the scientific data presented.
These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including without limitation uncertainty of success in the development and potential commercialization of BIIB092 and/or BIIB054; the risk that we may not fully enroll our clinical trials or enrollment will take longer than expected; unexpected concerns may arise from additional data, analysis or results obtained during our clinical trials; regulatory authorities may require additional information or further studies, or may fail or refuse to approve or may delay approval of our drug candidates, including BIIB092 and/or BIIB054; the occurrence of adverse safety events; unexpected costs or delays; we may encounter other unexpected hurdles; failure to protect and enforce our data, intellectual property and other proprietary rights and uncertainties relating to intellectual property claims and challenges; and product liability claims. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. Investors should consider this cautionary statement, as well as the risk factors identified in our most recent annual or quarterly report and in other reports we have filed with the Securities and Exchange Commission. These statements are based on our current beliefs and expectations and speak only as of the date of this press release. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.
1 Kalia LV, Lang AE. Parkinson’s disease, Lancet. 2015 Aug 29;386(9996):896-912
+1 617 679 4945
+1 781 464 2442
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg saker fra GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra GlobeNewswire
Kim Crawford Wines Partners With US Open Tennis Championships25.6.2019 16:00:00 CEST | Pressemelding
No. 1-Selling Sauvignon Blanc in U.S. Becomes the Official Wine of the US Open Tennis Championships in New, Multi-Year Agreement WHITE PLAINS, N.Y. and MARLBOROUGH, New Zealand, June 25, 2019 (GLOBE NEWSWIRE) -- The United States Tennis Association (USTA) and Kim Crawford Wines today announced a new partnership that names Kim Crawford Wines as the official wine of the US Open Tennis Championships. The new, multi-year agreement commences with the 2019 Open. The No. 1-selling Sauvignon Blanci and leading New Zealand wine brandii in the U.S., Kim Crawford Wines will #ServeUpKim to US Open fans with a permanent brand presence on the grounds of the USTA Billie Jean King National Tennis Center. Kim Crawford will further support the partnership at retail locations across the country with impactful displays and an exciting sweepstakes, in which the winner will receive an all-expenses paid VIP experience at the 2020 US Open. The sweepstakes begins July 1 and ends August 31, during which consume
Appian Announces Winners of its Annual Hackathon at Appian World25.6.2019 15:00:00 CEST | Pressemelding
RESTON, Va., June 25, 2019 (GLOBE NEWSWIRE) -- Appian (NASDAQ: APPN) congratulates the winners of the Appian World 2019 Hackathon. Participants were tasked with leveraging the Appian platform to showcase the effectiveness and speed of low-code development. Hundreds of registrations were narrowed down to three winners by a seasoned panel of judges including Black Girls Code Founder and CEO, Kimberly Bryant and Neil Ward-Dutton, IDC’s VP of AI and DX European Research Practices and Appian executives. Finalists attended Appian World 2019 in San Diego, CA where they showcased their solutions to the all-star panel of judges. The judges based their decisions on the originality of the idea underlying the application, how well that idea was executed by the developer, and the beneficial impact of the solution. The submissions, covering a variety of industries and use cases, all exemplified the power and simplicity of building enterprise applications on the Appian platform. The 2019 winners are:
Painter 2020 Empowers Digital Artists to Achieve Their Perfect Vision25.6.2019 15:00:00 CEST | Pressemelding
New streamlined workflow, GPU-based brushing, and convenient color selection come together in the fastest Painter yet OTTAWA, June 25, 2019 (GLOBE NEWSWIRE) -- Painter 2020, the latest version of the industry’s most powerful and creative digital painting software, sets the standard for professional digital art on macOS and Windows. Allowing artists to realize their creative vision faster than ever, the new Painter® 2020 dramatically accelerates performance across virtually any system, while delivering a streamlined workflow, all-new brushes, enhanced color selection, and more. “Painter continues to redefine today’s professional digital art workflow,” said Chris Pierce, Senior Product Manager for Digital Arts at Corel. “Whether you’re running the latest hardware or your tried-and-true machine, this new version is an absolute game-changer. From experimenting with color to working with layers, the tools you rely on every day are now more accessible and intuitive.” “By leveraging GPU techn
XBiotech Announces Dr. Alice Gottlieb to Chair Upcoming Phase 2 Study of Bermekimab in Hidradenitis Suppurativa25.6.2019 14:45:00 CEST | Pressemelding
AUSTIN, Texas, June 25, 2019 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announces that Alice Gottlieb M.D., Ph.D., will Chair the Company’s upcoming Phase II study in Hidradenitis Suppurativa (HS). Dr. Gottlieb is Medical Director of dermatology at the Mount Sinai Beth Israel Campus, and Clinical Professor at the Icahn School of Medicine at Mount Sinai. She is one of few doctors in the nation board certified in Dermatology, Rheumatology and Internal Medicine. This will be the second study Chaired by Dr. Gottlieb involving bermekimab in HS and the third study conducted for the drug in HS. Dr. Gottlieb received an M.D.-Ph.D. from The Rockefeller University-Cornell University Medical College. Dr. Gottlieb founded the Tufts Dermatology residency program (which formally was shared with Boston University) and served as Chair of Dermatology and Dermatologist-in-Chief of Tufts Medical Center. She also founded the Dermatology Division at UMDNJ-Robert Wood Johnson Medical School where she serve
Mitsubishi Heavy Industries to Acquire Canadair Regional Jet Program from Bombardier Inc.25.6.2019 14:00:00 CEST | Pressemelding
MHI now positioned to transform and lead the underserved regional jet business , with bolster ed customer support services Key step in MHI’s strategy of expanding its aircraft business globally, with a mid-term focus on North America Completes Bombardier’s aerospace transformation and refocus on business aviation TOKYO and MONTRÉAL, June 25, 2019 (GLOBE NEWSWIRE) -- Mitsubishi Heavy Industries, Ltd (MHI) (TOKYO:7011) and Bombardier Inc (TSX: BBD.B) announced today they have entered into a definitive agreement, whereby MHI will acquire Bombardier’s regional jet program for a cash consideration of $550 million USD, payable to Bombardier upon closing, and the assumption by MHI of liabilities amounting to approximately $200 million USD. Under the agreement, Bombardier’s net beneficial interest in the Regional Aircraft Securitization Program (RASPRO), which is valued at approximately $180 million USD, will be transferred to MHI. Pursuant to the agreement, MHI will acquire the maintenance, s
VSBLTY SELECTED BY ENERGETIKA TECHNOLOGIES TO PROVIDE CROWD ANALYTICS TO ENHANCE SAFETY LIGHTING & SECURITY THROUGHOUT LATIN AMERICA25.6.2019 13:44:00 CEST | Pressemelding
Philadelphia, PA, June 25, 2019 (GLOBE NEWSWIRE) -- VSBLTY Groupe Technologies Corp. (CSE: VSBY) (Frankfurt: 5VS) (OTC: VSBGF), a leading retail software and technology company, is teaming with Energetika, an international provider of “intelligent lighting” solutions, to install safety lighting and integrated security to Mexico City, and other Latin American cities designated as a “Smart City.” Accessibility, habitability, sustainability, air quality, noise levels, energy, health and economic vitality are among the elements necessary to be selected as a “Smart City.” Energetika is a leading provider of smart lighting solutions for economically efficient applications that incorporate security. Energetika chose VSBLTY to provide security technology that includes crowd analytics and facial recognition for residential, commercial and governmental applications. VSBLTY technology provides enhanced customer engagement and audience measurement using machine learning and computer vision. Its in